Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
UBS
Healthtrust
US Department of Justice
Moodys
Cerilliant
McKesson
McKinsey
Daiichi Sankyo

Generated: July 21, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: clozapine

« Back to Dashboard

clozapine Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Barr Labs Inc clozapine 090308 100MG TABLET, ORALLY DISINTEGRATING;ORAL
Barr Labs Inc clozapine 090308 25MG TABLET, ORALLY DISINTEGRATING;ORAL
Mylan Pharms Inc clozapine 201824 100MG TABLET, ORALLY DISINTEGRATING;ORAL
Mylan Pharms Inc clozapine 201824 12.5MG TABLET, ORALLY DISINTEGRATING;ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Fuji
Baxter
Cipla
Boehringer Ingelheim
Covington
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.